HomeCompareCASI vs FCPT

CASI vs FCPT: Dividend Comparison 2026

CASI yields 1328.90% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CASI wins by $234399211.74M in total portfolio value
10 years
CASI
CASI
● Live price
1328.90%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$234399211.79M
Annual income
$204,175,493,351,581.47
Full CASI calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — CASI vs FCPT

📍 CASI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCASIFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CASI + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CASI pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASI
Annual income on $10K today (after 15% tax)
$112,956.81/yr
After 10yr DRIP, annual income (after tax)
$173,549,169,348,844.25/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, CASI beats the other by $173,549,169,343,935.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASI + FCPT for your $10,000?

CASI: 50%FCPT: 50%
100% FCPT50/50100% CASI
Portfolio after 10yr
$117199605.92M
Annual income
$102,087,746,678,678.38/yr
Blended yield
87.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CASI right now

CASI
Analyst Ratings
6
Buy
Consensus: Buy
Price Target
$6.00
+3886.7% upside vs current
Range: $6.00 — $6.00
Altman Z
-48.0
Piotroski
3/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASI buys
0
FCPT buys
0
No recent congressional trades found for CASI or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCASIFCPT
Forward yield1328.90%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$234399211.79M$49.1K
Annual income after 10y$204,175,493,351,581.47$5,775.28
Total dividends collected$232170679.18M$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$6.00$27.00

Year-by-year: CASI vs FCPT ($10,000, DRIP)

YearCASI PortfolioCASI Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$143,590$132,890.37$11,401$700.92+$132.2KCASI
2$1,936,985$1,783,343.56$13,064$864.84+$1.92MCASI
3$24,555,470$22,482,896.19$15,051$1,072.48+$24.54MCASI
4$292,647,488$266,373,134.40$17,442$1,337.22+$292.63MCASI
5$3,280,034,702$2,966,901,889.89$20,340$1,677.08+$3280.01MCASI
6$34,587,635,943$31,077,998,811.82$23,880$2,116.57+$34587.61MCASI
7$343,283,883,424$306,275,112,965.10$28,241$2,689.36+$343283.86MCASI
8$3,208,243,320,650$2,840,929,565,386.25$33,660$3,442.07+$3208243.29MCASI
9$28,246,465,831,874$24,813,645,478,778.85$40,456$4,439.95+$28246465.79MCASI
10$234,399,211,791,687$204,175,493,351,581.47$49,063$5,775.28+$234399211.74MCASI

CASI vs FCPT: Complete Analysis 2026

CASIStock

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Full CASI Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this CASI vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASI vs SCHDCASI vs JEPICASI vs OCASI vs KOCASI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.